Highlights:

Pivotal Alzheimer’s disease trial remains on track for topline final results in November this year with third positive independent Data Monitoring Committee (DMC) recommendation

Strong ongoing enrolment in open-label extension (OLE) phase of the trial with 88% of main trial participants choosing to immediately continue in the OLE where they receive active Xanamem® therapy

Positive scientific advice received from the European Medicines Agency generally aligned with prior US FDA advice

Peer-reviewed depression trial manuscript detailing positive anti-depressant activity published in British Journal of Psychiatry

The first national acceptances received for new patents covering Xanamem treatment of cognitive decline in healthy elderly persons and key manufacturing steps

June-end cash balance of $16.7m provides cash runway beyond XanaMIA trial final results to mid-2027.

® Xanamem is a registered trademark of Actinogen Medical Limited